AI assistant
Neurogene Inc. — Director's Dealing 2017
May 10, 2017
33497_dirs_2017-05-10_2e9837b7-68a7-466f-a463-1835d21e02b3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2017-05-08
Reporting Person: Pelzer Robert (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-08 | Stock Option (Right to Buy) | $13.74 | A | 9000 | Acquired | 2027-05-07 | Common Stock (9000) | Direct |
Footnotes
F1: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 8, 2017 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date.